Swiss Recommendations for Cutaneous Basal Cell Carcinoma.

Details

Ressource 1Download: Swiss Recommendations for Cutaneous Basal Cell Carcinoma.pdf (222.40 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_9BDB4B95DB8E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
Journal
Dermatology
Author(s)
Ramelyte E., Nägeli M.C., Hunger R., Merat R., Gaide O., Navarini A.A., Cozzio A., Wagner N.B., Maul L.V., Dummer R.
ISSN
1421-9832 (Electronic)
ISSN-L
1018-8665
Publication state
Published
Issued date
2023
Peer-reviewed
Oui
Volume
239
Number
1
Pages
122-131
Language
english
Notes
Publication types: Practice Guideline ; Review
Publication Status: ppublish
Abstract
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in Switzerland and worldwide. Most BCCs can be treated in a curative setting. However, patients can develop locally destructive and, rarely, metastatic tumors that require a different treatment approach. The clinical subtype of individual lesions provides prognostic information and influences management decisions. Surgical excision, topical therapies, and radiotherapy are highly effective in the majority of subtypes as well as in low- and high-risk diseases. For patients with low-risk diseases and superficial tumors not amenable to surgery, several nonsurgical alternatives are available. Systemic therapy is indicated for high-risk BCCs, which are not amenable to either surgery or radiotherapy. Hedgehog pathway inhibitors (HHI) are currently approved. Other therapeutic options such as immune checkpoint inhibitors show promising results in clinical trials. This first version of Swiss recommendations for diagnosis and management of BCC was prepared through extensive literature review and an advisory board consensus of expert dermatologists and oncologists in Switzerland. The present guidelines recommend therapies based on a multidisciplinary team approach and rate of recurrence for individual lesions. Based on the risk of recurrence, two distinct groups have been identified: low-risk (easy-to-treat) and high-risk (difficult-to-treat) tumors. Based on these classifications, evidence-based recommendations of available therapies are presented herein.
Keywords
Humans, Antineoplastic Agents/therapeutic use, Carcinoma, Basal Cell/therapy, Carcinoma, Basal Cell/drug therapy, Hedgehog Proteins/metabolism, Hedgehog Proteins/therapeutic use, Skin Neoplasms/therapy, Skin Neoplasms/drug therapy, Switzerland, Basal cell carcinoma, Hedgehog pathway inhibitors, Locally advanced tumor, Metastatic tumor, PD-1 inhibitors
Pubmed
Web of science
Open Access
Yes
Create date
04/10/2022 11:37
Last modification date
22/06/2024 7:17
Usage data